← All trials
NCT04707352
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 8, 2021
- Primary completion
- Jan 16, 2022
- Completion date
- May 30, 2022
- First posted
- Jan 13, 2021
- Last posted
- Feb 12, 2021
- Enrollment
- 162
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaLead sponsor
- Hospital Clínica Universitario Virgen de la Arrixaca (SPAIN)Overall official - principal investigator
- Spanish Society of CardiologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.